Cipla Limited (CIPLA) Fair Value & Analysis
Healthcare · IN · Market cap ₹1.2T
Fair value as of: Aug 13, 2026
From 26 valuation models · updated today
Fair value updated Aug 13, 2026, revised from ₹1,001 to ₹1,801 (+80.0%) since Jul 13, 2026. Share price +1.4% over the past month.
A solid business, screening 23% undervalued on our models.
What matters now
- Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (₹1,166 to ₹2,247) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹825.37 – ₹1,648 · fair‑value band ₹1,166 – ₹2,247 · the ₹1,459 price screens below the ₹1,801 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Cipla Limited (CIPLA) currently trades at ₹1,459, while our model-based Fair Value estimate is ₹1,801, implying the stock looks roughly 23.5% undervalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Cipla Limited generated revenue of ₹278B at a net margin of 13.9%. Revenue declined 2.1% year over year. It earns a return on equity of 11.7%. The balance sheet holds a net cash position of ₹6.9B. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹1,166 (bear case) to ₹2,247 (bull case); at ₹1,459, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 12% below its 52-week high and 26% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 23%, CIPLA screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (₹2,231) versus Dividend Discount (₹275.21). Highest evidence: Growth DCF (80).
Notify me when CIPLA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 58
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally.
Full company description
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Cipla Limited reported revenue of ₹282B in FY2026 versus ₹217B in FY2022, a compound +6.7%/yr. Reported net income was ₹38.8B in FY2026, compounding +11.4%/yr from FY2022.
of which total revenue +8.4 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch CIPLA: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
| Aurobindo Pharma Limited AUROPHARMA | ₹1,667 | ₹1,340 | -20% |
Compare Cipla Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cipla Limited (CIPLA) overvalued or undervalued?
What is the fair value of CIPLA?
What is the quality score of CIPLA?
What is the revenue of Cipla Limited (CIPLA)?
What is the net profit margin of CIPLA?
Does Cipla Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Cipla Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.